pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 31 Non-oncology: 18
Oncology: 13
Under Consideration for Negotiation 20 Non-oncology: 8
Oncology: 12
Completed Negotiations 885 With Letter of Intent: 768
Without agreement: 117
Negotiations That Were Not Pursued 114

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Movantik Knight Therapeutics Inc. Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Omvoh Eli Lilly Canada Inc. Crohn's disease

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks